After @ weeks , the patients in the dapsone arm showed mean improvement over baseline in VAS ( @ -LSB- @ % CI , @-@ @ -RSB- , P = @ ) , urticaria score ( -@ -LSB- @ % CI , -@ to -@ -RSB- , P = @ ) , and itch score ( -@ -LSB- @ % CI , -@ to -@ -RSB- , P = @ ) , whereas the placebo arm showed no improvement over baseline for VAS , urticaria , or itch scores .